Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

PDI's Ceftin Primary Care Sales Force Could Transition To Another Product

  • News

Executive Summary

Professional Detailing, Inc. expects to transition its Ceftin sales force to another product after it ceases primary care promotion of the GlaxoSmithKline antibiotic.

You may also be interested in...



PDI/Bayer Detailing Focuses On Cipro, Avelox After Baycol Withdrawal

PDI and Bayer are discussing which product will replace Bayer's withdrawn cholesterol-lowering agent Baycol in their contract sales agreement

PDI/Bayer Detailing Focuses On Cipro, Avelox After Baycol Withdrawal

PDI and Bayer are discussing which product will replace Bayer's withdrawn cholesterol-lowering agent Baycol in their contract sales agreement

Ranbaxy Generic Ceftin Closer To Launch With Appellate Court Ruling

GlaxoSmithKline is not likely to win its Ceftin (cefuroxime axetil) patent infringement case against Ranbaxy, a D.C. federal appellate court said in an Aug. 20 ruling.

Table

View full table

Tags:
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS038414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By